A meta-analysis has suggested that the addition of a DPP-4 inhibitor to existing sulphonylurea (SU) therapy is associated with a 50% increased risk of hypoglycaemia in type 2 diabetes patients and one excess case for every 17 patients treated in the first six months. These findings emphasise the importance of following the recommendation to reduce SU dose when commencing a DPP-4 inhibitor.